UCL School of Life and Medical Sciences

2013

• Lampe F, Speakman A, Sherr L, Phillips A, Collins S, Gilson R, Johnson M, Fisher M, Wilkins E, Anderson J, Daskalopoulou M, Edwards S, McDonnell J, Perry N, Jones M, O'Connell R, Lascar M, Hart G, Johnson A, Miners A, Geretti A, Burman W, Elford J, Rodger A (2013). Psychological and physical symptoms and sexual behaviour among HIV-diagnosed men who have sex with men (MSM) in the UK. HIV MEDICINE, 14, 2 - 2.
• Rodger A, Phillips A, Sturgeon K, Sewell J, Asboe D, Fedele S, Nwokolo N, Gilson R, De Esteban N, Jennings L, Gompels M, Allan S, Clay S, Engler B, Wandolo E, Campbell L, Hobbs K, Fisher M, Perry N, Dhar J, Mashonganyika L, O'Connell R, Tawana C, Bruun T, Cambiano V, Collins S, Nightingale A, Lundgren J (2013). Continued high levels of condomless sex in serodifferent couples when the positive partner is on antiretroviral therapy: the PARTNER study. HIV MEDICINE, 14, 8 - 8.
• Winston A, Jose S, Gibbons S, Back D, Stohr W, Post F, Fisher M, Gazzard B, Nelson M, Gilson R, Orkin C, Johnson M, Palfreeman A, Chadwick D, Leen C, Schwenk A, Anderson J, Gompels M, Dunn D, Khoo S, Sabin C, UK Collaborative HIV Cohort Study (2013). Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring.. J Antimicrob Chemother, 68(6), 1354 - 1359. doi:10.1093/jac/dkt029

2012

• Rodger AJ, Lodwick R, Schecter M (2012). Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT Trials compared to the general population. AIDS, , - .
• Lampe F, Speakman A, Phillips A, Sherr L, Gilson R, Johnson M, Fisher M, Wilkins E, Anderson J, Edwards S, McDonnell J, Perry N, Aderogba K, Hart G, Johnson A, Collins S, Elford J, Miners A, Geretti A, Burman B, Rodger A (2012). ART use, viral suppression, and sexual behaviour among HIV-diagnosed MSM in the UK: results from the Antiretrovirals, Sexual Transmission Risk and Attitudes (ASTRA) Study.. J Int AIDS Soc, 15(6), 18143 - .
• Sultan BJ, Fish R, Carrick G, Gilson R, Robinson A, Mercey D, White J, Benn P (2012). IS POOLING OF SELF-TAKEN SPECIMENS AN EFFECTIVE AND ACCEPTABLE METHOD OF TESTING FOR SEXUALLY TRANSMITTED INFECTIONS IN MSMS?. SEXUALLY TRANSMITTED INFECTIONS, 88, A42 - A43. doi:10.1136/sextrans-2012-050601c.98
• Lampe F, Speakman A, Phillips A, Sherr L, Gilson R, Johnson M, Fisher M, Anderson J, Wilkins E, Broussard C, McDonnell J, Perry N, Scourse R, George V, Hart G, Johnson A, Collins S, Miners A, Elford J, Geretti A-M, Burman W, Rodger A (2012). Depression and virological status among UK HIV outpatients: results from a multicentre study. HIV MEDICINE, 13, 4 - 4.
• Milinkovic A, Pavlou M, Furco A, Copas A, Arenas-Pinto A, Connolly JO, Edwards S, Gilson R, Williams I (2012). Factors associated with increased risk of tenofovir-related renal toxicity: case-control study. HIV MEDICINE, 13, 52 - 52.
• Kober C, Johnson M, Fisher M, Hill T, Anderson J, Bansi L, Gompels M, Palfreeman A, Dunn D, Gazzard B, Gilson R, Post F, Phillips AN, Walsh J, Orkin C, Delpech V, Ainsworth J, Leen C, Sabin CA, UK Collaborative HIV Cohort (CHIC) Study (2012). Non-uptake of highly active antiretroviral therapy among patients with a CD4 count < 350 cells/μL in the UK.. HIV Med, 13(1), 73 - 78. doi:10.1111/j.1468-1293.2011.00956.x
• Gompels M, Dunn DT, Phillips A, Dooley D, De Burgh Thomas A, Anderson J, Post F, Pillay D, Gazzard B, Hill T, Johnson M, Gilson R, Bansi L, Easterbrook P, Fisher M, Walsh J, Orkin C, Ainsworth J, Leen C, Sabin C, UK Collaborative HIV Cohort (UK CHIC) Study (Appendix) (2012). Does discordancy between the CD4 count and CD4 percentage in HIV-positive individuals influence outcomes on highly active antiretroviral therapy?. J Infect Dis, 205(4), 540 - 547. doi:10.1093/infdis/jir380
• Barber TJ, Harrison L, Asboe D, Williams I, Kirk S, Gilson R, Bansi L, Pillay D, Dunn D, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort (UK CHIC) Study Steering Committees (2012). Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor.. J Antimicrob Chemother, 67(4), 995 - 1000. doi:10.1093/jac/dkr569
• Price H, Bansi L, Sabin CA, Bhagani S, Burroughs A, Chadwick D, Dunn D, Fisher M, Main J, Nelson M, Pillay D, Rodger A, Taylor C, Gilson R, UK Collaborative HIV Cohort Hepatitis Group, Steering Committee (2012). Hepatitis B virus infection in HIV-positive individuals in the UK collaborative HIV cohort (UK CHIC) study.. PLoS One, 7(11), e49314 - . doi:10.1371/journal.pone.0049314
• Nebbia G, Peppa D, Schurich A, Khanna P, Singh HD, Cheng Y, Rosenberg W, Dusheiko G, Gilson R, ChinAleong J, Kennedy P, Maini MK (2012). Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection.. PLoS One, 7(10), e47648 - . doi:10.1371/journal.pone.0047648
• Bansi L, Gazzard B, Post F, Phillips A, Johnson M, Hill T, Gilson R, Leen C, Walsh J, Fisher M, Sabin C, UK Collaborative HIV Cohort Study (2012). Biomarkers to monitor safety in people on art and risk of mortality.. J Acquir Immune Defic Syndr, 60(1), 51 - 58. doi:10.1097/QAI.0b013e31824d2134

2011

• Nebbia G, Peppa D, Schurich A, Khanna P, Singh H, Rosenberg W, Dusheiko G, Gilson R, Chinaleong J, Kennedy P, Maini M (2011). Role of the TIM-3/Galectin-9 pathway in chronic hepatitis B infection.
• Sethi G, Edwards S, Gilson R, Sabin C (2011). Treatment outcomes in Black and Minority Ethnic (BME) and White men who have sex with men (MSM). HIV MED, 12, 15 - 15.
• Nathan M, Sheaff M, Fox P, Goon P, Gilson R, Lacey C (2011). ANAL NEOPLASIA AND CANCER Early treatment of anal intraepithelial neoplasia. BRITISH MEDICAL JOURNAL, 343, - . doi:10.1136/bmj.d7717
• Waters L, Fisher M, Anderson J, Wood C, Delpech V, Hill T, Walsh J, Orkin C, Bansi L, Gompels M, Phillips A, Johnson M, Gilson R, Easterbrook P, Leen C, Porter K, Gazzard B, Sabin C, for the UK CHIC Steering Committee (2011). Authors' response to Drs Scourfield, Jackson and Nelson.. HIV Med, 12(7), 450 - 451. doi:10.1111/j.1468-1293.2011.00932.x
• Woodhall SC, Jit M, Soldan K, Kinghorn G, Gilson R, Nathan M, Ross JD, Lacey CJ, QOLIGEN study group (2011). The impact of genital warts: loss of quality of life and cost of treatment in eight sexual health clinics in the UK.. Sex Transm Infect, 87(6), 458 - 463. doi:10.1136/sextrans-2011-050073
• Hughes RA, Sterne JA, Walsh J, Bansi L, Gilson R, Orkin C, Hill T, Ainsworth J, Anderson J, Gompels M, Dunn D, Johnson MA, Phillips AN, Pillay D, Leen C, Easterbrook P, Gazzard B, Fisher M, Sabin CA (2011). Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study.. HIV Med, 12(10), 583 - 593. doi:10.1111/j.1468-1293.2011.00929.x
• Whitlock GG, Lowndes CM, Mercey DE, Gilson R (2011). Do HIV-infected individuals test for sexually transmitted infections at another sexual health clinic?. Sex Transm Infect, 87(3), 253 - . doi:10.1136/sti.2010.049072
• Whitlock G, Warwick Z, Perry N, Ottewill M, Richardson D, Fisher M, Gilson R (2011). Why do men who have sex with men who are at high risk of HIV infection decline HIV testing?. HIV MED, 12, 65 - 65.
• Peppa D, Micco L, Schurich A, Nebbia G, Khanna P, Singh H, Rosenberg W, Dusheiko G, Gilson R, Maini M (2011). FRATRICIDE OF HBV-SPECIFIC CD8 T CELLS BY NK CELLS MEDIATED THROUGH THE TRAIL PATHWAY.
• Garvey L, Winston A, Walsh J, Post F, Porter K, Gazzard B, Fisher M, Leen C, Pillay D, Hill T, Johnson M, Gilson R, Anderson J, Easterbrook P, Bansi L, Orkin C, Ainsworth J, Phillips AN, Sabin CA, UK Collaborative HIV Cohort CHIC (2011). HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. EUR J NEUROL, 18(3), 527 - 534. doi:10.1111/j.1468-1331.2010.03291.x
• Garvey L, Winston A, Walsh J, Post F, Porter K, Gazzard B, Fisher M, Leen C, Pillay D, Hill T, Johnson M, Gilson R, Anderson J, Easterbrook P, Bansi L, Orkin C, Ainsworth J, Palfreeman A, Gompels M, Phillips AN, Sabin CA, UK Collaborative HIV Cohort (CHIC) study (2011). Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease.. Neurology, 76(8), 693 - 700. doi:10.1212/WNL.0b013e31820d8b0b
• Albert M, Benito J, Bhagani S, Boesecke C, Deterding K, Dominguez S, Fisher M, Fontanet A, Garcia D, Gilson R, Guiguet M, Hoepelman AIM, Horban A, Katlama C, Mallolas J, Page E, Peters L, Pozniak A, Prins M, Puoti M, Rauch A, Rodger A, Rockstroh JK, Soriano V, Stephan C, Thibault V, Tural C, Valantin MA, van de Laar T, van der Meer J, Vella S, Vogel M, de Wit S, Autran B, Clotet B, Danta M, Journiac M, Matthews G, Meyer-Olson D, Nelson M, Schmidt R, Wedemeyer H, European AIDS Treatment Network NE (2011). Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference The European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel. AIDS, 25(4), 399 - 409. doi:10.1097/QAD.0b013e328343443b
• Nathan M, Sheaff M, Fox P, Goon P, Gilson R, Lacey C (2011). Early treatment of anal intraepithelial neoplasia.. BMJ, 343, d7717 - .
• May M, Gompels M, Delpech V, Porter K, Post F, Johnson M, Dunn D, Palfreeman A, Gilson R, Gazzard B, Hill T, Walsh J, Fisher M, Orkin C, Ainsworth J, Bansi L, Phillips A, Leen C, Nelson M, Anderson J, Sabin C (2011). Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study.. BMJ, 343, d6016 - .
• Barber TJ, Geretti AM, Anderson J, Schwenk A, Phillips AN, Bansi L, Gilson R, Hill T, Walsh J, Fisher M, Johnson M, Post F, Easterbrook P, Gazzard B, Palfreeman A, Orkin C, Leen C, Gompels M, Dunn D, Delpech V, Pillay D, Sabin CA, UK CHIC Study Steering Committee (2011). Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study.. Antivir Ther, 16(6), 805 - 814. doi:10.3851/IMP1818
• Waters L, Fisher M, Anderson J, Wood C, Delpech V, Hill T, Walsh J, Orkin C, Bansi L, Gompels M, Phillips A, Johnson M, Gilson R, Easterbrook P, Leen C, Porter K, Gazzard B, Sabin C, UK CHIC Steering Committee (2011). Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late starters.. HIV Med, 12(5), 289 - 298. doi:10.1111/j.1468-1293.2010.00881.x
• Peppa D, Gill U, Micco L, Schurich A, Nebbia G, Singh H, Rosenberg W, Gilson R, Kennedy PT, Maini M (2011). Susceptibility of T cells to death ligand-mediated deletion in the liver of chronic hepatitis B virus (CHB) infected patients.

2010

• Turner J, Bansi L, Gilson R, Gazzard B, Walsh J, Pillay D, Orkin C, Phillips A, Easterbrook P, Johnson M, Porter K, Schwenk A, Hill T, Leen C, Anderson J, Fisher M, Sabin C (2010). The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK - trends in HCV testing and the impact of HCV on HIV treatment outcomes. Journal of Viral Hepatitis, 17(8), 569 - 577.
• Richens J, Copas A, Sadiq ST, Kingori P, McCarthy O, Jones V, Hay P, Miles K, Gilson R, Imrie J, Pakianathan M (2010). A randomised controlled trial of computer-assisted interviewing in sexual health clinics.. Sex Transm Infect, 86(4), 310 - 314. doi:10.1136/sti.2010.043422
• Cozzi-Lepri A, Dunn D, Pillay D, Sabin CA, Fearnhill E, Geretti AM, Hill T, Kaye S, Bansi L, Smit E, Johnson M, Burns S, Gilson R, Cameron S, Easterbrook P, Zuckerman M, Gazzard B, Walsh J, Fisher M, Orkin C, Ainsworth J, Leen C, Gompels M, Anderson J, Phillips AN, Babiker A, Porter K, Sadiq T, Schwenk A, Mackie N, Winston A, Delpech V, UK Collaborative Grp HIV Drug Resi , UK CHIC Study Grp (2010). Long-Term Probability of Detecting Drug-Resistant HIV in Treatment-Naive Patients Initiating Combination Antiretroviral Therapy. CLIN INFECT DIS, 50(9), 1275 - 1285. doi:10.1086/651684
• Turner J, Aarons E, O'Farrell S, Price H, Ferns B, Copas A, Gilson R (2010). Hepatitis C viral load in semen of HIV-positive men during acute and chronic hepatitis C infection.
• Hill T, Bansi L, Sabin C, Phillips A, Dunn D, Anderson J, Easterbrook P, Fisher M, Gazzard B, Gilson R, Johnson M, Leen C, Orkin C, Schwenk A, Walsh J, Winston A, Babiker A, Delpech V, UK Collaborative HIV Cohort Study Group (2010). Data linkage reduces loss to follow-up in an observational HIV cohort study.. J Clin Epidemiol, 63(10), 1101 - 1109. doi:10.1016/j.jclinepi.2009.12.007
• Turner J, Bansi L, Gilson RJC, Gazzard B, Walsh J, Pillay D, Orkin C, Phillips A, Easterbrook P, Johnson M, Porter K, Schwenk A, Hill T, Leen C, Anderson J, Fisher M, Sabin C, on behalf of the UK Collaborative HIV Cohort (UK CHIC) study (2010). The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK – trends in HCV testing and the impact of HCV on HIV treatment outcomes.. Journal of Viral Hepatitis, 17, 569 - 577.
• Bansi L, Sabin C, Delpech V, Hill T, Fisher M, Walsh J, Chadborn T, Easterbrook P, Gilson R, Johnson M, Porter K, Anderson J, Gompels M, Leen C, Ainsworth J, Orkin C, Nelson M, Rice B, Phillips A, UK Collaborative HIV Cohort (CHIC) Study and the Health Protection Agency (2010). Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations.. HIV Med, 11(7), 432 - 438. doi:10.1111/j.1468-1293.2009.00809.x
• Brook G, Main J, Nelson M, Bhagani S, Wilkins E, Leen C, Fisher M, Gilleece Y, Gilson R, Freedman A, Kulasegaram R, Agarwal K, Sabin C, Deacon-Adams C, BHIVA Viral Hepatitis Working Group (2010). British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010.. HIV Med, 11(1), 1 - 30. doi:10.1111/j.1468-1293.2009.00781.x
• Stohr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, Pillay D, Hill T, Ainsworth J, Gazzard B, Leen C, Bansi L, Fisher M, Orkin C, Anderson J, Johnson M, Easterbrook P, Gibbons S, Khoo S, UK CHIC Steering Comm (2010). Factors influencing lopinavir and atazanavir plasma concentration. J ANTIMICROB CHEMOTH, 65(1), 129 - 137. doi:10.1093/jac/dkp408
• Ray M, Logan R, Sterne JAC, Hernandez-Diaz S, Robins JM, Sabin C, Bansi L, van Sighem A, de Wolf F, Costagliola D, Lanoy E, Bucher HC, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Justice A, Gouler J, Lodi S, Phillips A, Seng R, Meyer L, Perez-Hoyos S, de Olalla PG, Herman MA, Phillips AN, Gilson R, Easterbrook P, Fisher M, Gazzard B, Johnson M, Walsh J, Leen C, Orkin C, Anderson J, Pillay D, Delpech V, Schwenk A, Dunn D, Gompels M, Hill T, Porter K, Babiker A, Sabin C, HIV-CAUSAL Collaboration (2010). The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS, 24(1), 123 - 137. doi:10.1097/QAD.0b013e3283324283
• Sabin CA, Schwenk A, Johnson MA, Gazzard B, Fisher M, Walsh J, Orkin C, Hill T, Gilson R, Porter K, Easterbrook P, Delpech V, Bansi L, Leen C, Gompels M, Anderson J, Phillips AN, UK CHIC Steering Comm (2010). Late diagnosis in the HAART era: proposed common definitions and associations with mortality. AIDS, 24(5), 723 - 727. doi:10.1097/QAD.0b013e328333fa0f

2009

• Grant AD, Bansi L, Ainsworth J, Anderson J, Delpech V, Easterbrook P, Fisher M, Gazzard B, Gilson R, Gompels M, Hill T, Johnson M, Leen C, Orkin C, Phillips AN, Porter K, Post F, Walsh J, Sabin CA, United Kingdom Collaborative HIV C (2009). Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention? United Kingdom Collaborative HIV Cohort Study Group. AIDS, 23(18), 2507 - 2515. doi:10.1097/QAD.0b013e3283320dfd
• Bansi L, Turner J, Gilson R, Post F, Gazzard B, Leen C, Anderson J, Porter K, Hill T, Fisher M, Ainsworth J, Pillay D, Johnson M, Winston A, Orkin C, Easterbrook P, Phillips A, Sabin C, on behalf of the UK Collaborative HIV Cohort CHIC Study (2009). Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study. Journal of Acquired Immune Deficiency Syndromes, 52(3), 391 - 396. doi:10.1097/QAI.0b013e3181ab73cc
• Gilson R, Ross J, Maw R, Rowen D, Sonnex C, Lacey CJN (2009). A multi-centre, randomised, double-blind, placebo-controlled study of cryotherapy versus cryotherapy and podophyllotoxin cream as treatment for external anogenital warts.. Sexually Transmitted Infections, Epub, - . doi:10.1136/sti.2009.038075
• Bower M, Fisher M, Hill T, Reeves I, Walsh J, Orkin C, Phillips A, Bansi L, Gilson R, Easterbrook P, Johnson M, Gazzard B, Leen C, Pillay D, Schwenk A, Anderson J, Porter K, Gompels M, Sabin CA, for the UK Collaborative HIV Cohort CHIC Study (2009). CD4 counts and the risk of systemic non-Hodgkin’s lymphoma in individuals with HIV in the UK.. Haematologica, 94(6), 875 - 880. doi:10.3324/haematol.2008.002691
• Peppa D, Dunn C, Pallant C, Das A, Khanna P, Dusheiko G, Gilson R, Maini MK (2009). The cytokine milieu impairs NK cell antiviral capacity in chronic HBV infection..
• Ewings F, Copas A, Fidler S, McLean K, Fisher M, Phillips A, Porter K, Hawkins D, Gilson R, Johnson M (2009). HIV-infected individuals co-infected with hepatitis C appear to have faster CD4 decline in the absence of ART but similar response once combination ART is initiated..
• Dunn C, Peppa D, Khanna P, Nebbia G, Jones M, Brendish N, Lascar RM, Brown D, Gilson RJ, Tedder RJ, Webster G, Dusheiko GM, Jacobs M, Klenerman P, Maini MK (2009). Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology, 137(4), 1289 - 1300. doi:10.1053/j.gastro.2009.06.054
• Sabin CA, Smith CJ, Delpech V, Anderson J, Bansi L, Gilson R, Schwenk A, Leen C, Gazzard B, Porter K, Mackie N, Fisher M, Orkin C, Johnson M, Easterbrook P, Hill T, Phillips AN, UK Collaborative HIV Cohort CHIC Study (2009). The associations between age, the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy.. HIV Medicine, 10(1), 35 - 43. doi:10.1111/j.1468-1293.2008.00654.x
• Bansi L, Sabin C, Gilson R, Gazzard B, Leen C, Anderson J, Dunn D, Hill T, Fisher M, Ainsworth J, Pillay D, Johnson M, Walsh J, Orkin C, Easterbrook P, Gompels M, Phillips A (2009). Virological response to initial antiretroviral regimens containing abacavir or tenofovir. The Journal of Infectious Diseases, 200, 710 - 714.
• Gilson R, Man S-L, Copas A, Rider A, Forsyth S, Hill T, Bansi L, Porter K, Gazzard B, Orkin C, Pillay D, Schwenk A, Johnson M, Easterbrook P, Walsh J, Fisher M, Leen C, Anderson J, Sabin CA, for the UK Collaborative HIV Cohort CHIC Study Group (2009). Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study. HIV Medicine, 11(2), 152 - 160. doi:10.1111/j.1468-1293.2009.00755.x

2008

• Pallant C, Christophides T, Khanna P, Dusheiko GM, Gilson RJ, Reynolds G, Adams DH, Maini MK, Dunn C (2008). CXCR6-directed recruitment of NK cells with pathogenic potential in HBV-related liver inflammation.
• Bansi L, Turner J, Gilson R, Sabin C (2008). What constitutes an ALT flare and which factors are associated with such flares?.
• United Kingdom Collaborative HIV Cohort Study , Lee KJ, Dunn D, Gilson R, Porter K, Bansi L, Hill T, Phillips AN, Sabin CA, Schwenk A, Leen C, Delpech V, Anderson J, Gazzard B, Johnson M, Easterbrook P, Walsh J, Fisher M, Orkin C (2008). Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study.. AIDS, 22(15), 1943 - 1950. doi:10.1097/QAD.0b013e32830e4cf3
• Porter K, Walker S, Hill T, Anderson J, Leen C, Johnson M, Gazzard B, Walsh J, Fisher M, Orkin C, Schwenk A, Gilson R, Easterbrook P, Delpech V, Sabin CA, on behalf of the UK CHIC Study Group (2008). Changes in outcome of persons initiating highly active antiretroviral therapy at a CD4 count less than 50 Cells/mm3. Journal of Acquired Immune Deficiency Syndromes, 47(2), 202 - 205. doi:10.1097/QAI.0b013e31815b1291
• Dunn C, Brendish N, Jones M, Nebbia G, Brown D, Gilson RJ, Dusheiko GM, Jacobs M, Maini MK (2008). Impaired innate immune responses in patients with early acute HBV infection.
• Bansi LK, Benzie AA, Phillips AN, Portsmouth S, Hill T, Leen C, Schwenk A, Johnson M, Anderson J, Gilson R, Easterbrook P, Gazzard B, Fisher M, Orkin C, Porter K, Pillay D, Taylor GP, Walsh JC, Sabin CA, for the UK Collaborative HIV Cohort CHIC Study (2008). Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?. AIDS, 22(3), 349 - 356. doi:10.1097/QAD.0b013e3282f4709a
• Ewings FM, Bhaskaran K, McLean K, Hawkins D, Fisher M, Fidler S, Gilson R, Nock D, Brettle R, Johnson M, Phillips A, Porter K, for the UK Register of HIV Seroconverters (2008). Survival following HIV infection of a cohort followed up from seroconversion in the UK. AIDS, 22(1), 89 - 95. doi:10.1097/QAD.0b013e3282f3915e
• Richens J, Copas A, Sadiq ST, Kingori P, McCarthy O, Jones V, Hay P, Miles K, Gilson R, Imrie J, Pakianathan M (2008). A three-arm randomised controlled trial comparing Computer-assisted Self-interview with Computer-assisted Physician Interview and Pen And Paper Face-to-face sexual history taking in a clinic setting..
• Stöhr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, Pillay D, Hill T, Ainsworth J, Pozniak A, Leen C, Bansi L, Fisher M, Orkin C, Anderson J, Johnson M, Easterbrook P, Gibbons S, Khoo S, on BOTLTDMDATUKCHICS (2008). Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antiviral Therapy, 13(5), 675 - 685.
• Cooksley H, Chokshi S, Maayan Y, Wedemeyer H, Andreone P, Gilson R, Warnes T, Paganin S, Zoulim F, Frederick D, Neumann AU, Brosgart CL, Naoumov NV (2008). Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4+ T-cell reactivity. Antimicrobial Agents and Chemotherapy, 52(1), 312 - 320. doi:10.1128/AAC.00467-07
• Giraudon I, Ruf M, Maguire H, Charlett A, Ncube F, Turner J, Gilson R, Fisher M, Bhagani S, Johnson M, Barton S (2008). Increase in diagnosed newly acquired hepatitis C in HIV-positive men who have sex with men across London and Brighton, 2002-2006: is this an outbreak?. Sexually Transmitted Infections, 84(2), 111 - 116. doi:10.1136/sti.2007.027334
• Turner J, Gikanga T, Jones V, Copas A, Cooper J, Stevens J, Aarons E, Gilson R (2008). Is there an unrecognised epidemic of hepatitis C infection in men who have sex with men?.
• Cozzi-Lepri A, Dunn D, Pillay D, Sabin C, Fearnhill E, Phillips A, and TUKHIVDRDAUKCHICSG (2008). Long-term probability of detecting HIV drug resistance in drug-naïve patients starting currently recommended first-line combination ART..
• Easterbrook PJ, Phillips AN, Hill T, Matthias R, Fisher M, Gazzard B, Gilson R, Scullard G, Johnson M, Dunn DT, Orkin C, Anderson J, Schwenk A, Leen C, Sabin CAOBOTUKCHIVCCHICSSC (2008). Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK. HIV Medicine, 9(1), 47 - 56.
• Gompels M, Sabin C, Phillips A, Dunn D, and TUKCHIVCCHICS (2008). The frequency and clinical implications of a discordant CD4 count and CD4 percentage.
• Peppa D, Dunn C, Pallant C, Das A, Ellis G, Gilson R, Maini M (2008). IMPAIRED INNATE IMMUNE RESPONSES IN PATIENTS WITH CHRONIC HBV INFECTION. J INFECTION, 57(5), 428 - 429.
• Lopes AR, Kellam P, Das A, Dunn C, Kwan A, Turner J, Peppa D, Gilson RJ, Gehring A, Bertoletti A, Maini MK (2008). Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection. Journal of Clinical Investigation, 118(5), 1835 - 1845. doi:10.1172/JCI33402
• Dunn C, Nebbia G, Jones M, Brendish N, Gilson RJ, Tedder RJ, Dusheiko GM, Jacobs M, Klenerman P, Maini MK (2008). Silencing of the early innate immune response in patients with acute hbv infection.

2007

• Phillips AN, Leen C, Wilson A, Anderson J, Dunn D, Schwenk A, Orkin C, Hill T, Fisher M, Walsh J, Pillay D, Bansi L, Gazzard B, Easterbrook P, Gilson R, Johnson M, Sabin CAUKCHIVCCHICS (2007). Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study. The Lancet, 370(9603), 1923 - 1928. doi:10.1016/S0140-6736(07)61815-7
• Phillips AN, Gilson R, Easterbrook P, Fisher M, Gazzard B, Johnson M, Walsh J, Leen C, Orkin C, Anderson J, Pillay D, Delpech V, Schwenk A, Dunn D, Gompels M, Hill T, Porter K, Babiker A, Sabin C (2007). HIV diagnosis at CD4 count above 500 Cells/mm(3) and progression to below 350 Cells/mm(3) without Antiretroviral therapy. JAIDS-J ACQ IMM DEF, 46(3), 275 - 278.
• Phillips AN, Gazzard B, Gilson R, Easterbrook P, Johnson M, Walsh J, Leen C, Fisher M, Orkin C, Anderson J, Pillay D, Delpech V, Sabin C, Schwenk A, Dunn D, Gompels M, Hill T, Porter K, Babiker A, UK Collaborative HIV Cohort Study (2007). Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS, 21(13), 1717 - 1721. doi:10.1097/QAD.0b013e32827038bf
• Benzie AA, Bansi LK, Sabin CA, Portsmouth S, Hill T, Johnson M, Gilson R, Easterbrook P, Gazzard B, Fisher M, Orkin C, Dunn D, Delpech V, Taylor GP, Walsh JC, Phillips AN, United Kingdom Collaborative HIV Cohort (CHIC) Study Group (2007). Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures.. AIDS, 21(11), 1423 - 1430. doi:10.1097/QAD.0b013e3281532ca7
• Ferns RB, Naoumov NV, Gilson RJ, Tedder RS (2007). Presence of hepatitis B virus core promoter mutations pre-seroconversion predict persistent viral replication after HBeAg loss.. Journal of Clinical Virology, 39(3), 199 - 204. doi:10.1016/j.jcv.2007.04.008
• UK CGOHDRUCHCSUROHS (2007). Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom. AIDS, 21(8), 1035 - 1039.
• Burns S, Cameron S, Cane P, Down P, Chrystie I, Churchill D, Delpech V, Pillay D, Dunn D, Fearnhill E, Green H, Porter K, Easterbrook P, Zuckerman M, Geretti AM, Gifford R, Kellam P, Pillay D, Phillips A, Sabin C, Goldberg D, Gompels M, Hale A, Kaye S, Leigh-Brown A, Orkin C, Pozniak A, Robb G, Smit E, Tilston P, Williams I, Ainsworth J, Anderson J, Babiker A, Delpech V, Dunn D, Easterbrook P, Fisher M, Gazzard B, Gilson R, Gompels M, Hill T, Johnson M, Leen C, Orkin C, Phillips A, Pillay D, Porter K, Sabin C, Sadiq T, Schwenk A, Walsh J, Babiker A, Brettle R, Darbyshire J, Delpech V, Easterbrook P, Fidler S, Gilson R, Goldberg D, Hawkins D, Jaffe H, Johnson A, Johnson M, McLean K, Phillips A, Pillay D, UK Collaborative Grp HIV Drug Re , UK CHIC Steering Comm , UK Register HIV Seroconverters Ste (2007). Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom. AIDS, 21(8), 1035 - 1039.
• Turner J, Gilson R (2007). Acute hepatitis C: presentation and outcome of early treatment..
• Nebbia G, Sabin CA, Dunn DT, Geretti AMUKCGOHIVDRUKCHIVCCHICSG (2007). Emergence of the H208Y mutation in the reverse transcriptase (RT) of HIV-1 in association with nucleoside RT inhibitor therapy. Journal of Antimicrobial Chemotherapy, 59(5), 1013 - 1016. doi:10.1093/jac/dkm067
• Hughes R, Sabin C, Sterne JAC, for TUKCHICSG (2007). Long-term trends in CD4 count in patients starting HAART: UK-CHIC study.
• Nebbia G, Garcia-Diaz A, Ayliffe U, Smith C, Dervisevic S, Johnson M, Gilson R, Tedder R, Geretti A-M (2007). Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons.. Journal of Medical Virology, 79(10), 1464 - 1471. doi:10.1002/jmv.20954
• Nebbia G, Garcia-Diaz A, Ayliffe U, Smith C, Dervisevie S, Johnson M, Gilson R, Tedder R, Geretti AM (2007). Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons. J MED VIROL, 79(10), 1464 - 1471. doi:10.1002/jmv.20954
• Stöhr W, Dunn D, Porter K, Hill T, Gazzard B, Walsh J, Gilson R, Easterbrook P, Fisher M, Johnson M, Delpech V, Phillips A, Sabin C, UK CHIC Study (2007). CD4 cell count and initiation of antiretroviral therapy: trends in seven UK centres, 1997-2003. HIV Medicine, 8(3), 135 - 141. doi:10.1111/j.1468-1293.2007.00443.x

2006

• Gilson R, Brook MG (2006). Hepatitis A, B, and C.. Sex Transm Infect, 82 Suppl 4, iv35 - iv39. doi:10.1136/sti.2006.023218
• Das A, Kennedy P, Lopes AR, Dunn C, Gilson RJ, Bertoletti A, Maini MK (2006). CD8 T cell hyporesponsiveness in chronic HBV infection: Role of CD3-zeta downregulation.
• Turner J, Bansi L, Gilson R, Sabin C (2006). Hepatitis C virus (HCV) co-infection in HIV-infected patients in the UK Collaborative HIV Cohort (CHIC) Study..
• Garcia A, Nebbia G, Ayliffe U, Smith C, Dervisevic S, Johnson M, Gilson R, Tedder R, Geretti A-M (2006). Occult hepatitis B in HIV-infected persons: prevalence, predictive factors and kinetics in response to HAART..
• Hopkins S, Barry O, Turner J, Johnson MA, Mulcahy F, Gilson R, Farrell G, Bhagani S, Bergin C (2006). Nadir CD4 does not predict response to pegylated-interferon and ribavirin in HIV-HCV co-infected patients..
• Maw ROBOTHPVSIGOBASHH (2006). Testing guidelines for individual sexually transmitted infections: Anogenital warts.. Sexually Transmitted Infections, 82(Supplement IV), iv40 - iv41.
• Gilson R, Brook MG (2006). Testing guidelines for individual sexually transmitted infections: Hepatitis A, B, and C.. Sexually Transmitted Infections, 82(Supplement IV), iv35 - iv39.
• Benzie A, Bansi L, Sabin C, Walsh J, Phillips A, for TUKCHICSG (2006). Viral rebound in patients on antiretroviral therapy with viral suppression: association with extent of previous virological failure and time with viral suppression.
• Grover D, Prime KP, Prince MV, Ridgway G, Gilson RJ (2006). Rectal gonorrhoea in men - is microscopy still a useful tool?. International Journal of STD and AIDS, 17(4), 277 - 279. doi:10.1258/095646206776253363

2005

• Smith CJ, Phillips AN, Hill T, Fisher M, Gazzard B, Porter K, Gilson R, Easterbrook P, Matthias R, Scullard G, Johnson MA, Sabin CA (2005). The rate of viral rebound after attainment of an HIV load <50 copies/mL according to specific antiretroviral drugs in use: results from a multicenter cohort study. The Journal of Infectious Diseases, 192(8), 1387 - 1397. doi:10.1086/466534
• Geretti AM, Sabin C, Dunn D, Nebbia G, on BOTUKCGOHIVDRATUKCHIVCCHICSG (2005). Mutations at reverse transcriptase (RT) codons G196, Q207, H208, R211 and L214 are associated with drug experience and specific RT mutation patterns..
• Phillips AN, Dunn D, Sabin C, Pozniak A, Matthias R, Geretti AM, Clarke J, Churchill D, Williams I, Hill T, Green H, Porter K, Scullard G, Johnson M, Easterbrook P, Gilson R, Fisher M, Loveday C, Gazzard B, Pillay D (2005). Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice.. AIDS, 19(5), 487 - 494.
• Gilson RJC, Ross J, Maw R, Rowen D, Sonnex C, Lacey CJN (2005). A multi-centre, randomised, double-blind, placebo-controlled study of cryotherapy versus cryotherapy and podophyllotoxin cream (Wartec®/Warticon®) as treatment for external anogenital warts..
• Stöhr W, Dunn D, Porter K, Sabin C (2005). CD4 cell count and starting ART: trends in six UK centres 1997 – 2002..
• Reeves I, Fisher M, Hill T, Sabin C, on BOTUKCHIVCCHICSC (2005). CD4 counts and the risk of lymphoma in individuals with HIV in the UK..
• Rider A, Gilson RJC, Sabin CA, on BOTUKCHICSC (2005). Discirdant CD4 and viral load responses in patients starting HAART in the UK Collaborative HIV Cohort (CHIC) Study..
• Turner J, Hopkins S, Mahungu T, Johnstone R, Lascar RM, Bhagani S, Dusheiko G, Johnson MA, Williams I, Gilson RJC (2005). Does nadir CD4 count in HIV-HCV co-infected patients predict HCV treatment response to pegylated interferon (p-IFN) and ribavirin (RBV)?.
• Danta M, Turner JM, Johnstone R, Lascar M, Johnson MA, Dusheiko GM, Williams IG, Gilson RJC, Bhagani S (2005). Early ribavirin improves sustained virological responses in acute HCV infection in HIV-positive individuals..
• Dunn C, Brunetto M, Flinchman D, Lampertico P, Meier U, Borrow P, Gilson RJ, Bertoletti A, Maini MK (2005). Immunomodulatory effects of the large fluctuations in IFN-γ and IL-8 accompanying hepatic flares in anti-HBe chronic HBV patients..
• Grover D, Allen L, Edwards SG, Green H, Copas A, Forsyth S, Pillay D, on BOTUKCGOHIVDRAUKCHIVCSUKCHIC (2005). Predictors of death, and response to therapy in patients with multi (three)-class drug resistant (MDR) HIV in the UK..
• Gilson R (2005). Sorting out genital warts. Trends in Urology Gynaecology and Sexual Health, 10(4), 26 - 30.
• Danta M, Turner JM, Johnstone R, Lascar RM, Johnson MA, Dusheiko GM, Williams IG, Gilson RJC, Bhagani S (2005). Use of pegylated interferon-alpha (peg-IFN) with or without ribavirin in the treatment of acute HCV in HIV-positive individuals..
• Grover D, Allen L, Pillay D, Green H, Copas A, Forsyth S, Edwards SG, on BOTUKCGOHIVDRAUKCHIVCSUKCHIC (2005). Virological and clinical outcomes in patients with multi (three)-class drug resistant (MDR) HIV in the UK..
• Easterbrook P, Bansi L, Sabin CA, Welz T, on BOTUKCHIVCCHICS (2005). What is the clinical significance of sustained low-level viraemia (SLLV) in patients on HAART?.
• Lascar RM, Lopes AR, Gilson RJC, Dunn C, Johnstone R, Copas A, Reignat S, Webster G, Bertoletti A, Maini MK (2005). Effect of HIV infection and antiretroviral therapy on hepatitis B virus (HBV)-specific T cell responses in patients who have resolved HBV infection. The Journal of Infectious Diseases, 191(7), 1169 - 1179. doi:10.1086/428502
• Brook MG, Gilson R, Wilkins EATBHIVAHC-IGCOBOTBHIVA (2005). BHIVA guidelines on HIV and chronic hepatitis: co-infection with HIV and hepatitis B virus infection.. HIV Medicine, 6(suppl 2), 84 - 95.
• Sabin CA, Hill T, Lampe F, Matthias R, Bhagani S, Gilson R, Youle MS, Johnson MA, Fisher M, Scullard G, Easterbrook P, Gazzard B, Phillips AN (2005). Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study. BMJ (Clinical Research Ed.), 330(7493), 695 - 699. doi:10.1136/bmj.38369.669850.8F

2004

• Pillay D, Green H, Gazzard B, Pozniak A, Matthias R, Johnson M, Churchill D, Fisher M, Hill T, Geretti AM, Clarke J, Cane P, Loveday C, Scullard G, Easterbrook P, Porter K, Williams I, Gilson R, Sabin C, Phillips A, Dunn D, UK Collaborative Grp HIV Drug (2004). Estimating resistance in drug experienced patients in the UK.
• Bhaskaran K, Pillay D, Walker AS, Fisher M, Hawkins D, Gilson R, McLean K, Porter K (2004). Do patients who are infected with drug-resistant HIV have a different CD4 cell decline after seroconversion? An exploratory analysis in the UK Register of HIV Seroconverters. AIDS, 18(10), 1471 - 1473.
• Haddow LJ, Bunn A, Copas AJ, Gilson R, Prince M, Ridgway G, Sadiq ST (2004). Polymorph count for predicting non-gonococcal urethral infection: a model using Chlamydia trachomatis diagnosed by ligase chain reaction.. Sexually Transmitted Infections, 80(3), 198 - 200. doi:10.1136/sti.2003.006924
• Phillips AN, Dunn D, Sabin C, Pozniak A, Matthias R, Geretti AM, Clarke J, Churchill D, Williams I, Hill T, Green H, Porter K, Scullard G, Johnson M, Easterbrook P, Gilson R, Fisher M, Loveday C, Gazzard B, Pillay D (2004). Risk of development of drug resistance in patients starting antiretroviral therapy with three or more drugs in routine clinical practice (abstract 135).
• Sabin C, Babiker A, Dunn D, Easterbrook P, Fisher M, Gilson R, Johnson M, Mortimer J, Peters B, Phillips A, Porter K, Scullard G, Gazzard B, Matthias R, Hill T (2004). The creation of a large UK-based multicentre cohort of HIV-infected individuals: The UK Collaborative HIV Cohort (UK CHIC) Study. HIV Medicine, 5(2), 115 - 124.
• Gilson RJC (2004). Viral hepatitis.. In Adler MA, Cowan F, French P, Mitchell H, Richens J (Ed.), ABC of Sexually Transmitted Infections (pp. 62 - 67). : BMJ Publishing Group Ltd.
• Das A, Lopes AR, Dunn C, Gotto J, Gilson RJ, Bertoletti A, Maini MK (2004). Downregulation of CD3 zeta chain: A mechanism for T-cell dysfunction in patients with chronic HBV infection..
• Turner JM, Johnstone R, Lascar RM, Williams I, Gilson RJC (2004). Outcome of acute hepatitis C in HIV positive men..

2003

• Prime KP, Grover D, Prince MV, Ridgway G, Gilson RJC (2003). Rectal gonorrhoea in men – is microscopy still a useful tool?.
• Brook MG, Gilson R, Wilkins EL, British HIVA (2003). BHIVA Guidelines: coinfection with HIV and chronic hepatitis B virus.. HIV Medicine, 4(Sup1), 42 - 51. doi:10.1046/j.1468-1293.4.s1.1.x
• Lascar RM, Smith A, Smith S, Macfarlane E, Gilson RJC (2003). Outcome of acute hepatitis C in HIV-positive homosexual men..
• Lascar RM, Gilson RJC, Lopes AR, Bertoletti A, Maini MK (2003). Reconstitution of hepatitis B virus (HBV)-specific T cell responses with treatment of human immunodeficiency virus/HBV coinfection. The Journal of Infectious Diseases, 188(12), 1815 - 1819. doi:10.1086/379896
• Creighton S, Prime K, Moore E, Bent P, Kelly M, Miller R, Gilson R (2003). Attendance at a young women’s clinic; more than contraception and STIs..
• Corden S, Ballard AL, Ijaz S, Barbara JA, Gilbert N, Gilson RJ, Boxall EH, Tedder RS (2003). HBV DNA levels and transmission of hepatitis B by health care workers. Journal of Clinical Virology, 27(1), 52 - 58. doi:10.1016/S1386-6532(02)00127-0

2002

• Tedder RS, Ijaz S, Gilbert N, Barbara JA, Corden SA, Gilson RJ, Boxall EH (2002). Evidence for a dynamic host-parasite relationship in e-negative hepatitis B carriers. Journal of Medical Virology, 68(4), 505 - 512. doi:10.1002/jmv.10241
• Cooksley H, Chokshi S, Wedemeyer H, Andreone P, Gilson R, Warnes T, Paganin S, Zoulim F, Jain A, James C, Gibbs C, Fry J, Brosgart C, Naoumov N (2002). Hepatitis B virus-specific T-cell reactivity during adefovir dipivoxil (ADV) treatment: A multicentre, controlled study. J HEPATOL, 36, 7 - 7.
• McSorley J, Gilson R (2002). Sexual disease in male patients.. Practitioner, 246(1641), 802 - 810.
• Cooksley H, Chokshi S, Wedemeyer H, Andreone P, Gilson RJC, Warnes T, Paganin S, Zoulim F, Jain A, James C, Gibbs C, Fry J, Brosgart C, Naoumov N (2002). Hepatitis B virus specific T-cell reactivity during adefovir dipivoxil (ADV) treatment: a multicentre, controlled study..
• Lascar RM, Johnstone R, Bertoletti A, Gilson RJC, Maini MK (2002). Impact of antiretroviral therapy on hepatitis B virus (HBV)-specific immune responses on HIV/HBV co-infected patients..
• McSorley J, Gilson R (2002). Sexual disease in male patients. Practitioner, 246(802), 807 - 810.

2001

• Heathcote EJ, Jeffers L, Perrillo R, Wright T, Sherman M, Gilson R, Shakil AO, Namini H, James C, Ho V, Xiong S, Fry J, Brosgart C (2001). Viral suppression and HBeAg-seroconversion following long-term adefovir dipivoxil therapy in chronic hepatitis B infection..
• Bell A, Ncube F, Hansell A, Davison KL, Young Y, Gilson RJC, Macdonald N, Heathcock R, Warburton F, Maguire H (2001). An outbreak of hepatitis A among young men associated with having sex in public venues.. Communicable Diseases Public Health, 4(3), 163 - 170.
• Gilson RJC, Mindel A (2001). Recent advances: Sexually transmitted infections. BMJ (Clinical Research Ed.), 322(7295), 1160 - 1164. doi:10.1136/bmj.322.7295.1160
• Heathcote EJ, Jeffers L, Perrillo R, Wright T, Sherman M, Gilson R, Shakil AO, Namini H, James C, Ho V, Fry J, Brosgart CL (2001). Serum HBV DNA suppression and seroconversion following long-term adefovir dipivoxil therapy in chronic hepatitis B patients.. HEPATOLOGY, 34(4), 316A - 316A.

2000

• Maini MK, Boni C, Lee K, Larrubia JR, Reignat S, Ogg GS, Herberg J, Gilson R, Alisa A, Williams R, Vergani D, Naoumov N, Ferrari C, Bertoletti A (2000). The role of virus-specific CD8+cells in liver damage and viral control during persistent hepatitis B virus infection. J HEPATOL, 32, 46 - 46.
• Maini MK, Boni C, Lee CK, Larrubia JR, Reignat S, Ogg GS, King AS, Herberg J, Gilson R, Alisa A, Williams R, Vergani D, Naoumov NV, Ferrari C, Bertoletti A (2000). The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. Journal of Experimental Medicine, 191(8), 1269 - 1280. doi:10.1084/jem.191.8.1269
• Smith AM, Williams IG, Gilson RJC (2000). Sexually acquired acute hepatitis C in homosexual men with HIV infection..

1999

• Gilson RJC, Shupack JL, Friedman-Kien AE, Conant MA, Weber JN, Nayagam AT, Swann RV, Pietig DC, Smith MH, Owens ML, and TISG (1999). A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients..
• Gilson RJC, Chopra KB, Newell AM, Murray-Lyon IM, Nelson MR, Rice SJ, Tedder RS, Toole J, Jaffe HS, Weller IVD (1999). A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. Journal of Viral Hepatitis, 6(5), 387 - 395. doi:10.1046/j.1365-2893.1999.00182.x
• UK Register of HIV Seroconverters Steering Committee (1999). How soon after HIV seroconversion is antiretroviral therapy initiated?. AIDS, 13(10), 1241 - 1247.
• Gilson RJC, Weller IVD (1999). Hepatitis and human immunodeficiency virus infection in homosexual men and injecting drug users. In McIntyre N, Benhamou J-P, Bircher J, Rizzetto M, Rodes J (Ed.), Oxford Textbook of Clinical Hepatology (pp. 965 - 973). : .
• Rooney G, Higgins J, Cowan FM, Gilson RJC (1999). Systematic review of sexual transmission of hepatitis C virus infection..

1998

• Gilson RJC, de Ruiter A, Waite J, Ross E, Loveday C, Howell DR, Tedder RS, Weller IVD (1998). Hepatitis B virus infection in patients attending a genitourinary medicine clinic: risk factors and vaccine coverage. Sexually Transmitted Infections, 74(2), 110 - 115. doi:10.1136/sti.74.2.110
• Weller IVD, Gilson RJC (1998). Viral Hepatitis. In Adler MW (Ed.), ABC of Sexually Transmitted Diseases (pp. 28 - 32). : BMJ Books.
• Rooney G, Johnstone R, Bean P, Williams D, Gilson RJC, Williams IG (1998). Use of protease inhibitors in HIV infected patients co-infected with chronic hepatitis B: a case series..
• UK Register of HIV Seroconverters Steering Committee (1998). The AIDS incubation period in the UK estimated from a national register of HIV seroconverters. AIDS, 12(6), 659 - 667.
• Rooney G, Gilson RJC (1998). Sexual transmission of hepatitis C virus infection. Sexually Transmitted Infections, 74(6), 399 - 404. doi:10.1136/sti.74.6.399
• Heathcote EJ, Jeffers L, Wright T, Sherman M, Perrillo R, Sacks S, Canthers R, Rugizi V, Di Biseeglie A, Baian V, Murray A, Rooney G, Jaffe HS, for TADHBVST (1998). Loss of serum HBV DNA and HBeAg and seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: two placebo-controlled phase II studies..
• Chokshi S, Papakonstantinou A, Gilson RJC, Johnstone R, Lopes AR, Weller IVD, Williams R, Naoumov NV (1998). Hepatitis flares in patients with adefovir dipivoxil correlate with activation of hepatitis B core-specific T cell reactivity..
• Gilson RJC, Murray-Lyon I, Nelson MR, Rice SJ, Tedder RS, Murray A, Jaffe HS, Weller IVD (1998). Extended treatment with adefovir dipivoxil in patients with chronic hepatitis B virus infection..
• Gilson RJC, Murray-Lyon I, Nelson MR, Rice SJ, Tedder RS, Murray A, Jaffe HS, Weller IVD (1998). Extended treatment with adefovir dipivoxil in patients with chronic hepatitis B virus infection.

1997

• Rooney G, Direkze N, Copas A, Gilson RJC (1997). Can we improve compliance with hepatitis B vaccination in genitourinary medicine clinics?.
• Heptonstall J, Barnes J, Burton E, Chattopadyhay B, McMillan L, Sullivan K, Tarling R, Viniker D, Boxall E, Cartmill I, Chatterjea M, Neill R, Collins M, Gill N, Ngui SL, Parker C, Ryan M, Teo CG, Coyle P, Craske J, Paver K, Gilson R, Hawkins A, Tedder R, Watts P, Zuckerman M, Morris D, Nazareth B (1997). Transmission of hepatitis B to patients from four infected surgeons without hepatitis B e antigen. NEW ENGL J MED, 336(3), 178 - 184.
• Fakoya A, Matear PM, Filley E, Rook GAW, Stanford J, Gilson RJC, Beecham N, Weller IVD, Vyakarnam A (1997). HIV infection alters the production of both type 1 and type 2 cytokines but does not induce a polarised type 1 or type 2 state. AIDS, 11(12), 1445 - 1452. doi:10.1097/00002030-199712000-00008
• Gilson RJ, Hawkins AE, Beecham MR, Ross E, Waite J, Briggs M, McNally T, Kelly GE, Tedder RS, Weller IV (1997). Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS, 11(5), 597 - 606. doi:10.1097/00002030-199705000-00007
• The IITAO (1997). Transmission of hepatitis B to patients from four infected surgeons without hepatitis B e antigen. New England Journal of Medicine, 336(3), 178 - 184. doi:10.1056/NEJM199701163360304
• Gilson RJC (1997). Review of last month's publications. Keeping abreast of adverse events. AIDS Targeted Information, 11, R137 - R138.

1996

• UK Register of HIV Seroconverters Steering Committee (1996). The UK register of HIV seroconverters: methods and analytical issues. Epidemiology and Infection, 117(2), 305 - 312. doi:10.1017/S0950268800001485
• Tang KY, Chan T, Fenton KA, Gilson RJC (1996). Hepatitis B in the Chinese community in Britain. BRIT MED J, 312(7029), 507 - 507.
• Gilson RJC, Chopra K, Murray-Lyon I, Newell M, Nelson M, Tedder RS, Toole J, Jaffe HS, Hellmann N, Weller IVD (1996). A placebo-controlled phase I/II study of adefovir dipivoxil (bis-POM-PMEA) in patients with chronic hepatitis B infection..
• Gilson RJC, Chopra K, Murray-Lyon I, Newell M, Nelson M, Tedder RS, Toole J, Jaffe HS, Hellmann N, Weller IVD (1996). A placebo-controlled phase I/II study of adefovir dipivoxil (bis-POM-PMEA) in patients with chronic hepatitis B infection..
• Gilson RJC (1996). Early HIV infection - Clinical features and management.. In Mindel A, Miller R (Ed.), AIDS: A pocket book of diagnosis and management (pp. 42 - 54). : Arnold.
• Zuckerman M, Hawkins A, Heptonstall J, Watts P, Gilson R, Tedder R (1996). Hepatitis B transmission involving anti-HBe carrier surgeons - HBV DNA and nucleotide sequence analysis..
• Hawkins AE, Zuckerman MA, Briggs M, Gilson RJC, Goldstone AH, Brink NS, Tedder RS (1996). Hepatitis B nucleotide sequence analysis: linking an outbreak of acute hepatitis B to contamination of a cryopreservation tank.. Journal of Virological Methods, 60, 81 - 88.
• Gilson RJC (1996). Hepatitis B and admission to medical school - More flexibility should allow infectious applicants to follow non-invasive medical careers. BRIT MED J, 313(7061), 830 - 831.
• Maini NK, Gilson RJ, Chavda N, Gill S, Fakoya A, Ross EJ, Phillips AN, Weller IVD (1996). Reference ranges and sources of variability of CD4 counts in HIV-seronegative women and men. Genitourinary Medicine, 72(1), 27 - 31. doi:10.1136/sti.72.1.27
• Hawkins AE, Zuckerman MA, Goldstone AH, Gilson RJC, Heptonstall J, Tedder RS, et A (1996). Identification of a common source outbreak of hepatitis B infection in a bone marrow transplant facility by nucleotide sequence analysis..
• Hawkins AE, Gilson RJC, Gilbert N, Wreghitt TG, Gray JJ, Ahlers-de Boer I, Tedder RS, Alexander GJM (1996). Hepatitis B virus surface mutations associated with infection after liver transplantation. Journal of Hepatology, 24(1), 8 - 14. doi:10.1016/S0168-8278(96)80179-6

1995

• FAKOYA A, MATEAR PM, FILLEY E, ROOK GAW, STANFORD J, GILSON RJC, MAINI M, WELLER IVD, VYAKARNAM A (1995). TH1/TH2 OR TH0-QUESTIONABLE CYTOKINE PATTERNS IN HEALTHY HIV-INFECTED INDIVIDUALS. J CELL BIOCHEM, , 205 - 205.
• Weller IVD, Gilson RJC (1995). Viral hepatitis. In Adler M (Ed.), ABC of Sexually Transmitted Diseases (pp. 28 - 31). : John Wiley & Sons.
• Zuckerman MA, Hawkins AE, Briggs M, Waite J, Balfe P, Gilson RJC, Tedder RS (1995). The investigation of hepatitis B transmission in an health care setting - application of direct sequence analysis.. The Journal of Infectious Diseases, 172, 1080 - 1083.
• Fakoya A, Matear PM, Filley E, Rook GAW, Stanford J, Gilson RJC, Maini M, Weller IVD, Vyakarnam A (1995). TH1/TH2 or TH0-questionable cytokine patterns in healthy HIV-infected individuals. (Abstract D4-219).
• Mookerjee VS, Mannino MV, Gilson R (1995). Improving the performance stability of inductive expert systems under input noise. INFORM SYST RES, 6(4), 328 - 356.

1994

• Gilson RJC, Hawkins AE, Tedder RS, Weller IVD (1994). In-vitro suppression of hepatitis B virus DNA polymerase activity by 9-(2-phosphonylmethoxyethyl) adenine..
• Hawkins AE, Gilson RJC, Bickerton EA, Tedder RS, Weller IVD (1994). Conservation of precore and core sequences of hepatitis B virus in chronic viral carriers.. Journal of Medical Virology, 43(1), 5 - 12. doi:10.1002/jmv.1890430103
• Hawkins AE, Gilson RJC, Beath SV, Boxall EH, Kelly DA, Tedder RS, Weller IVD (1994). Novel application of a point mutation assay: evidence for transmission of hepatitis B viruses with precore mutations and their detection in infants with fulminant hepatitis B.. Journal of Medical Virology, 44(1), 13 - 21. doi:10.1002/jmv.1890440105

1993

• Maini M, Manning P, Gilson RJC (1993). Impotence - all in the head?.
• Noble PR, Gilson RJC (1993). Hepatitis C: recent advances.. Maternal and Child Health, 18, 70 - 74.
• Hawkins AE, Gilson RJC, Gilbert N, Boxall EH, Hatzakis A, Tedder RS, Weller IVD (1993). Clinical significance of hepatitis B virus mutants: application of a novel assay for point mutations..
• Sweeney BJ, Manji H, Gilson RJC, Harrison MJG (1993). Optic neuritis and HIV-1 infection.. Journal of Neurology, Neurosurgery and Psychiatry, 56(6), 705 - 707. doi:10.1136/jnnp.56.6.705
• Maini M, Gilson RJC, Adolphus N, Fakoya A, Ross E, Phillips AN (1993). Normal range and sources of variability of CD4 counts in HIV-seronegative women and heterosexual men..

1992

• Gill SK, Loveday C, Gilson RJC (1992). Transmission of HIV-1 by oroanal intercourse. Genitourinary Medicine, 68(4), 254 - 257.
• Gilson RJC (1992). Sexually transmitted hepatitis: a review.. Genitourinary Medicine, 68(2), 123 - 129.
• Gilson RJC, Semple M, Gill SK, Loveday C, Tedder RS, Weller IVD (1992). Lack of suppression by ribavirin of HIV viraemia. (Letter). The Lancet, 339, 1605 - 1606.
• HAWKINS A, GILSON R, TEDDER RS, WREGHITT TG, ALEXANDER GJM (1992). HEPATITIS-B VIRUS ESCAPE MUTANT FOLLOWING LIVER-TRANSPLANTATION. HEPATOLOGY, 16(4), A204 - A204.
• Gilson R (1992). Hepatitis B vaccination: who, when, and why?. Prescriber, 3, 94 - 100.
• French PD, Gilson RJC (1992). Conference Report: The International Society for STD Research Ninth International Meeting, Banff, Canada, October 1991. Genitourinary Medicine, 68(3), 189 - 191.
• GILSON RJC, SEMPLE M, GILL SK, LOVEDAY C, TEDDER RS, WELLER IVD (1992). LACK OF SUPPRESSION BY RIBAVIRIN OF HIV VIREMIA. LANCET, 339(8809), 1605 - 1606.
• GILL SK, LOVEDAY C, GILSON RJC (1992). TRANSMISSION OF HIV-1 INFECTION BY OROANAL INTERCOURSE. GENITOURIN MED, 68(4), 254 - 257.

1991

• Gilson RJC, Weller IVD (1991). Hepatitis and human immunodeficiency virus infection in homosexual men and injecting drug users. In McIntyre N, Benhamou J-P, Bircher J, Rizzetto M, Rodes J (Ed.), Oxford Textbook of Clinical Hepatology (pp. 1311 - 1318). : Oxford University Press.
• Miller RF, Gilson R, Hage C, Scaravilli F, Michaels L (1991). HIV-associated dilated cardiomyopathy.. Genitourinary Medicine, 67, 453 - 459.
• Gill SK, Gilson RJC, Rickards D (1991). Multiple prostatic abscesses presenting with urethral discharge. Genitourinary Medicine, 67(5), 411 - 412. doi:10.1136/sti.67.5.411
• Gilson RJC, Hawkins AE, Kelly G, Gill S, Weller IVD (1991). No effect of zidovudine on hepatitis B virus replication in homosexual men with symptomatic HIV-1 infection. AIDS, 5(2), 217 - 220.
• FLETCHER C, GILSON M, GILSON R, SCHILLING R (1991). JOHN-GILSON-CHAIR-OF-OCCUPATIONAL-MEDICINE. BRIT J IND MED, 48(9), 648 - 648.
• Kani J, Nandwani R, Gilson RJ, Johnson AM, Maguire HC, Tedder RS (1991). Hepatitis A virus infection among homosexual men (Letter). BMJ (Clinical Research Ed.), 302(6789), 1399 - .
• KANI J, GILSON RJC, NANDWANI R, JOHNSON AM, MAGUIRE HC, TEDDER RS (1991). HEPATITIS-A VIRUS-INFECTION AMONG HOMOSEXUAL MEN. BRIT MED J, 302(6789), 1399 - 1399.
• Bhatti N, Gilson RJC, Beecham M, Williams P, Matthews MP, Tedder RS, Weller IVD (1991). Failure to deliver hepatitis B vaccine: confessions from a genitourinary medicine clinic. BMJ (Clinical Research Ed.), 303(6794), 97 - 101. doi:10.1136/bmj.303.6794.97
• Tedder RS, Gilson RJ, Briggs M, Loveday C, Cameron CH, Garson JA, Kelly GE, Weller IV (1991). Hepatitis C virus: evidence for sexual transmission. BMJ (Clinical Research Ed.), 302(6788), 1299 - 1302. doi:10.1136/bmj.302.6788.1299

1990

• Gilson RJC, De Ruiter A, Waite J, Loveday C, Kelly G, Weller IVD (1990). Seroprevalence of hepatitis B virus infection in patients attending a genitourinary medicine clinic.
• Hawkins A, Gilson RJC, Tedder RS, Weller IVD (1990). Interactions between hepatitis B virus (HBV) and HIV in homosexual men..
• Gilson RJC, Tedder RS, Garson J, Briggs M, Loveday C, Weller IVD (1990). Hepatitis C virus infection: another sexually transmitted disease?.
• Gilson RJC (1990). Early HIV infection - Clinical features and management. In Mindel A (Ed.), AIDS: A pocket book of diagnosis and management. (pp. 33 - 46). : Edward Arnold.

1989

• Gilson RJC, Tedder RS, Weller IVD (1989). Hepatitis B: reactivation or reinfection associated with HIV-1 infection. The Lancet, 2(8675), 1330 - .

1988

• GILSON RJC, TIMMINS DJ (1988). CHLAMYDIAL INFECTION. CURR OPIN INFECT DIS, 1(1), 16 - 20.
• Gilson R (1988). Clinical aspects of AIDS. Medicine International, 57, 2344 - 2352.
• Gilson RJC, Timmins DJ (1988). Genital chlamydial infection.. Current Opinion in Infectious Disease, 1, 16 - 20.
• Gilson RJC, Weller IVD, Hawkins A, Waite J C, C A R, A J K, G B, M T, R S (1988). Interactions between hepatitis B virus (HBV) and HIV in homosexual men..
• Waite J, Gilson RJC, Weller IVD, Lacey CJN, Hambling MH, Hawkins A, Briggs M, Tedder RS (1988). Hepatitis B virus reactivation or reinfection associated with HIV-1 infection. AIDS, 2(6), 443 - 448. doi:10.1097/00002030-198812000-00006

1987

• Gilson RJC, Weller IVD (1987). Human immunodeficiency virus (HIV) infection for the general physician.. Postgraduate Medical Journal, 63, 427 - 433.

1986

• BINGHAM JS, GILSON RJC (1986). AIDS - HOW MUCH HAVE WE LEARNED. PRACTITIONER, 230(1420), 851 - &.

• United KCHIVCSG (). Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention?. AIDS, , - .